CACNA1A and Alzheimer disease: We find evidence that the pathway is active in hAPP transgenic mouse models in vivo and human AD brains and demonstrate that either pharmacological CaV2.1 inhibition or genetic CaV2.1 haploinsufficiency is sufficient to normalize neurotransmitter release.